

Neurofibromatosis Therapeutic Acceleration Program
111 posts

@ntapresearch
Accelerating the development of effective therapeutics for plexiform and cutaneous neurofibromas



🚨 Application for the 2025 Drug Discovery Initiative is OPEN! NF researchers, this is your chance to advance innovative therapies and repurposed treatments or validate new NF targets. Deadline: February 2, 2026 by 4 PM EST 🔗 Apply now: go.ctf.org/ddi #EndNF

NF1 is frequently mutated in #glioblastoma, yet therapies targeting this alteration often fall short. @VasuLabUCSF & team @UCSF now show NF1 mutant glioblastomas exhibit prognostic signatures with distinct sensitivity to MEK inhibition: insight.jci.org/articles/view/…

Honoring Verena Staedtke’s vision, @JohnsHopkins researchers, led by Renyuan Bai w/ support from Jaishri Blakeley at @ntapresearch, are advancing gene therapy for NF1. An AAV vector delivering neurofibromin shows promise + hope for patients. buff.ly/R4pRpoD

#FDA approves a treatment for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. ow.ly/3hbP50Xu7Tg

Are you an early-career clinician-scientist? Ready to make an impact on NF1 research? Join us for an information session on the Francis Collins Scholars Program. Wednesday, October 1, 2025 @ 10 AM EST 🔗 Register here: forms.office.com/r/nGqDFnN2B3 #Research #EndNF #NF1
















Please join us in welcoming our amazing summer interns to BRIDGE Lab! We’re thrilled to have Tali, Catalina, and Annetta join the team. Each of them brings curiosity, enthusiasm, and fresh perspective to our work, and we’re excited to learn and grow together this summer.

